CSP
PFE icon

Cary Street Partners’s Pfizer PFE Stock Holding History

Cary Street Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.71M Buy
153,898
+14,274
+10% +$373K 0.08% 244
2026
Q1 		$3.92M Sell
139,624
-112,283
-45% -$2.99M 0.1% 218
2025
Q4 		$6.27M Sell
251,907
-9,954
-4% -$251K 0.16% 147
2025
Q3 		$6.67M Buy
261,861
+16,705
+7% +$412K 0.17% 138
2025
Q2 		$5.94M Buy
245,156
+14,817
+6% +$346K 0.17% 145
2025
Q1 		$5.84M Buy
230,339
+101,194
+78% +$2.65M 0.18% 130
2024
Q4 		$3.43M Buy
+129,145
New +$3.5M 0.11% 178

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Cary Street Partners's PFE Position: Q2 2026 in Review

Cary Street Partners increased its Pfizer (PFE) stake by 10% in Q2 2026, buying an estimated $373K and bringing the position to 153,898 shares worth $3.71M. The position accounts for 0.08% of the portfolio, ranked #244.

Cary Street Partners first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.67M in Q3 2025. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Cary Street Partners held 153,898 shares of Pfizer worth $3.71M as of Q2 2026.
  • Cary Street Partners bought 14,274 Pfizer shares in Q2 2026, an estimated $373K.
  • Pfizer made up 0.08% of Cary Street Partners's portfolio in Q2 2026, its #244 holding.
  • Cary Street Partners first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • Cary Street Partners's Pfizer position peaked at $6.67M in Q3 2025.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.